Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Other Accumulated Expenses (2019 - 2023)

ADC Therapeutics has reported Other Accumulated Expenses over the past 5 years, most recently at $53.5 million for Q3 2023.

  • Quarterly results put Other Accumulated Expenses at $53.5 million for Q3 2023, down 14.64% from a year ago — trailing twelve months through Sep 2023 was $53.5 million (down 14.64% YoY), and the annual figure for FY2022 was $73.0 million, up 144532.35%.
  • Other Accumulated Expenses reached $53.5 million in Q3 2023 per ADCT's latest filing, roughly flat from $53.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $73.0 million in Q4 2022 and bottomed at $15430.0 in Q4 2019.
  • Median Other Accumulated Expenses over the past 5 years was $39.7 million (2021), compared with a mean of $32.5 million.
  • The largest annual shift saw Other Accumulated Expenses surged 175241.32% in 2021 before it dropped 14.64% in 2023.
  • Over 5 years, Other Accumulated Expenses stood at $15430.0 in 2019, then soared by 96.86% to $30375.0 in 2020, then surged by 66.25% to $50497.0 in 2021, then surged by 144532.35% to $73.0 million in 2022, then decreased by 26.77% to $53.5 million in 2023.
  • Business Quant data shows Other Accumulated Expenses for ADCT at $53.5 million in Q3 2023, $53.4 million in Q2 2023, and $57.4 million in Q1 2023.